Short Sellers Face Significant Risk Following New Guidance from Hims & Hers Health
In a noteworthy collaboration, Hims & Hers Health, a leading digital health platform (NYSE: HIMS), has teamed up with Novo Nordisk, the pharmaceutical company behind the FDA-approved weight loss drug, Wegovy (semaglutide). This partnership aims to enhance access to Wegovy through the Hims & Hers platform.
Under the terms of the agreement, Hims & Hers will offer a bundled package to customers. This package includes various dose strengths of Wegovy, as well as a membership for access to 24/7 care, ongoing clinical support, and nutrition guidance. The price for this package starts at $599 per month for cash-paying individuals without insurance [1][3][4].
The partnership enables patients to acquire Wegovy directly from Novo Nordisk's NovoCare Pharmacy via the Hims & Hers platform. This integration streamlines the process for patients to secure the medication along with comprehensive care support [1][3].
Long-term, the companies plan to collaborate on a roadmap to integrate Novo Nordisk's innovative medications with Hims & Hers' capacity to scale access to care. The goal is to deliver improved long-term outcomes for individuals dealing with chronic diseases more affordably [1][3][4].
A potential resolution of a past dispute between Hims & Hers and Novo Nordisk seems to have arisen over the sale of compounded versions of semaglutide, the key ingredient in Wegovy [2].
The announcement of this partnership led to a significant surge in Hims & Hers' stock, with shares jumping by 30% in premarket trading and closing 23% higher on the day of the announcement [2].
This collaboration between Hims & Hers Health and Novo Nordisk is not only about providing Wegovy, a FDA-approved weight loss drug, but also offering a comprehensive health-and-wellness package. The package includes different dose strengths of Wegovy, 24/7 care, clinical support, nutrition guidance, and access to therapies-and-treatments, all starting at $599 per month for customers without insurance. Moreover, the partnership intends to integrate more of Novo Nordisk's innovative medications with Hims & Hers' services, aiming to deliver affordable and improved long-term outcomes for individuals dealing with chronic diseases.
